Can MDCO Make Alnylam’s PCSK9 Candidate Work In The Hospital?

Lagging the antibodies in the PCSK9 race, MDCO’s candidate brings certain strengths, not the least being a fundamentally different mechanism. But where the big boys will target larger populations in multiple settings, MDCO is hunkering down in the channel it knows best – the hospital cath lab – counting on changing practice behavior to speed its uptake.

With only early-stage data in hand, The Medicines Co.’s (MDCO) PCSK9 candidate, the centerpiece of its budding lipid franchise, is far behind competitors. But MDCO is counting on a highly differentiated technology, as well as changing practice patterns among interventional cardiologists to help bolster the drug’s uptake. And its last-to-market position may enable it to take optimal advantage of evolving cholesterol management guidelines.

Last February, MDCO entered the PCSK9 race by licensing exclusive global rights to Alnylam Pharmaceuticals Inc.’s ALN-PCS program for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By 

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.